AAP
MAZE

Arax Advisory Partners’s Maze Therapeutics MAZE Stock Holding History

Arax Advisory Partners’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.59K Buy
+154
New +$4.04K ﹤0.01% 4618
2025
Q4 		– Sell
-307
Closed -$7.96K – 4620
2025
Q3 		$7.96K Buy
+307
New +$5.18K ﹤0.01% 2692

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Arax Advisory Partners's MAZE Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 154 shares worth $4.59K. The stake represents ﹤0.01% of the portfolio and ranks #4618 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in MAZE as recently as Q3 2025.

Arax Advisory Partners first reported a position in MAZE in Q3 2025 and has held it in 2 quarters since. The position peaked at $7.96K in Q3 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Arax Advisory Partners held 154 shares of Maze Therapeutics worth $4.59K as of Q2 2026.
  • Maze Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Maze Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4618 holding.
  • Arax Advisory Partners first reported a position in Maze Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Maze Therapeutics position peaked at $7.96K in Q3 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.